Aurobindo Pharma Clarifies Zentiva Acquisition Reports 'Premature', No Binding Pact Finalised
New Delhi: Aurobindo Pharma has clarified that reports of its potential acquisition of Prague-based generic drugmaker Zentiva are premature, stating that no binding agreement has been finalized.
In a regulatory filing on August 20, 2025, the company said it “regularly explores various strategic opportunities, including potential acquisitions and partnerships, which can enhance shareholder value.” However, it emphasized that “no binding agreement or definitive decision has been made by the Board of Directors of the Company in relation to the transaction referred to in the said article(s). Accordingly, the said news item is premature and should not be relied upon.”
Earlier, reports in The Economic Times suggested that Aurobindo Pharma was the frontrunner to acquire Zentiva from Advent International in a deal valued at USD 5–5.5 billion (Rs 43,500–47,900 crore). If completed at these valuations, the deal would become the largest-ever overseas acquisition by an Indian pharmaceutical company, surpassing Sun Pharma’s acquisition of Ranbaxy and Biocon Biologics’ acquisition of Viatris.
Also Read: Aurobindo Pharma to manufacture, supply HIV treatment cabotegravir across 133 countries
Reassuring investors, the company stated that any definitive developments will be promptly disclosed under SEBI Listing Regulations. “In the event of any definitive development requiring disclosure under the SEBI Listing Regulations, the Company will promptly make the necessary and timely announcements to the stock exchanges in accordance with applicable regulatory requirements,” Aurobindo said.
